Scholars Central

Conference abstractPublished 12 Mar 2018

The potential role and mechanism of STAT3 in acquired resistance to EGFR TKI in lung adenocarcinoma with EGFR mutation

Authors: Chao Ting-Ting, Kuo I-Hui

Cardinal Tien Hospital, Taiwan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Oncogene-addicted cancer cells generate a positive feedback loop leading to STAT3 activation after target drug therapy. The aim of this study was to suppress STAT3 pathway through elevating SHP-1 activity by SHP-1 enhancer. PC9 cell line is exon 19 deletion (746-750) of NSCLC and sensitive to TKI. PC9-Afatinib-resistance (PC9-AR) cell line is PC9 cell line treated with low dose Afatinib for more than 9 months. PC9-AR was resistant to Afatinib, but there was no T790M mutation in PC9-AR. SHP-1 enhancer, SC-43, was tested in PC9-AR and apoptosis and signal transduction was analyzed. By adding SC-43 caused growth inhibition and induced apoptosis in PC9-AR. SC-43 reduced STAT3 phosphorylation at tyrosine 705 in PC9-AR. PC9-AR expressed more EMT, which was also suppressed by SC-43. Ectopic expression of STAT3 in PC9 caused resistance to Afatinib. On the contrary, small interference RNA of STAT3 re-sensitized PC9-AR to Afatinib. Furthermore, SC-43 interacted with the N-SH2 domain of SHP-1 to enhance the activity of SHP-1 as its mechanism. SC-43 significantly reduced PC9-AR sphere formation and tumor growth in vivo through SHP-1/STAT3 pathway. SC-43 provides proof that targeting STAT3 signaling pathway may be a novel approach for the treatment in acquired resistance to EGFR TKI in lung adenocarcinoma with EGFR mutation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Chao Ting-Ting”
  • BylineArticles whose byline prints “Kuo I-Hui”